Seres Therapeutics (MCRB) Cash from Operations (2014 - 2026)
Seres Therapeutics (MCRB) posted Cash from Operations of 16360000.0 for Q1 2026, down 11.22% sequentially from 14710000.0 in Q4 2025, and down 160.8% YoY from 26910000.0 in Q1 2025.
Seres Therapeutics (MCRB) Cash from Operations (2014 - 2026) Analysis & Trends
Seres Therapeutics has reported Cash from Operations for 13 years, with the latest figure at 16360000.0 in Q1 2026.
- Quarterly Cash from Operations fell 160.8% year-over-year to 16360000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 42153000.0 (up 51.25% YoY) and the FY2025 annual result came in at 1117000.0, up 100.75% from the prior year.
- Cash from Operations declined to 16360000.0 in Q1 2026 per MCRB's latest filing, from 14710000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 65984000.0 in Q2 2023 and troughed at 76584000.0 in Q1 2023.
- A 5-year average of 30001294.12 and a median of 38882000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2026: Cash from Operations surged 232.24% in 2023, then plunged 160.8% in 2026.
- Over 5 years, Cash from Operations stood at 52892000.0 in 2022, then grew by 10.2% to 47499000.0 in 2023, then gained by 18.14% to 38882000.0 in 2024, then soared by 62.17% to 14710000.0 in 2025, then declined by 11.22% to 16360000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 16360000.0, 14710000.0, and 2206000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - | -22.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.39 Mn |
| Jun 30, 2026 | -22.39 Mn |
| Mar 31, 2026 | -16.36 Mn |
| Mar 31, 2026 | -16.36 Mn |
| Dec 31, 2025 | -14.71 Mn |
| Dec 31, 2025 | -14.71 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | -13.29 Mn |
| Jun 30, 2025 | -13.29 Mn |
| Mar 31, 2025 | 26.91 Mn |
| Mar 31, 2025 | 26.91 Mn |
| Dec 31, 2024 | -38.88 Mn |
| Dec 31, 2024 | -38.88 Mn |
| Sep 30, 2024 | -34.68 Mn |
| Sep 30, 2024 | -34.68 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Jun 30, 2024 | -39.81 Mn |
| Mar 31, 2024 | -35.24 Mn |
| Mar 31, 2024 | -35.24 Mn |